TY  - GEN
AB  - Adoptive T cell immunotherapy has shown significant promise in advanced melanoma, with over half of patients who failed standard treatments achieving objective clinical responses after receiving tumor‑specific T cells following nonmyeloablative lymphopenic conditioning. This work examines the T cell populations and molecular mechanisms that enhance anti‑tumor efficacy in this setting. We demonstrate that durable, potent anti‑tumor responses require the presence of both tumor‑specific CD4⁺ and CD8⁺ T cells in the lymphopenic host. Additionally, we show that T cells deficient in the ubiquitin‑specific protease Ubp43 exhibit superior therapeutic activity compared to wild‑type cells. These findings highlight key cellular components essential for effective adoptive T cell therapy and suggest a strategy to improve clinical outcomes by targeting Ubp43.
AD  - Oregon Health and Science University
AU  - Friedman, Kevin
DA  - 2009
DO  - 10.6083/M4QV3JHF
DO  - DOI
ED  - Fox, Bernard
ED  - Mentor
ID  - 357
KW  - Immune System
KW  - Immunotherapy
KW  - Neoplasms
KW  - CD8-Positive T-Lymphocytes
KW  - Adoptive Transfer
KW  - Melanoma
L1  - https://digitalcollections.ohsu.edu/record/357/files/358_etd.pdf
L2  - https://digitalcollections.ohsu.edu/record/357/files/358_etd.pdf
L4  - https://digitalcollections.ohsu.edu/record/357/files/358_etd.pdf
LK  - https://digitalcollections.ohsu.edu/record/357/files/358_etd.pdf
N2  - Adoptive T cell immunotherapy has shown significant promise in advanced melanoma, with over half of patients who failed standard treatments achieving objective clinical responses after receiving tumor‑specific T cells following nonmyeloablative lymphopenic conditioning. This work examines the T cell populations and molecular mechanisms that enhance anti‑tumor efficacy in this setting. We demonstrate that durable, potent anti‑tumor responses require the presence of both tumor‑specific CD4⁺ and CD8⁺ T cells in the lymphopenic host. Additionally, we show that T cells deficient in the ubiquitin‑specific protease Ubp43 exhibit superior therapeutic activity compared to wild‑type cells. These findings highlight key cellular components essential for effective adoptive T cell therapy and suggest a strategy to improve clinical outcomes by targeting Ubp43.
PB  - Oregon Health and Science University
PY  - 2009
T1  - Augmenting the effector phase of adoptive T cell immunotherapy of cancer
TI  - Augmenting the effector phase of adoptive T cell immunotherapy of cancer
UR  - https://digitalcollections.ohsu.edu/record/357/files/358_etd.pdf
Y1  - 2009
ER  -